vs
AtriCure, Inc.（ATRC）与FOSTER L B CO（FSTR）财务数据对比。点击上方公司名可切换其他公司
FOSTER L B CO的季度营收约是AtriCure, Inc.的1.1倍（$160.4M vs $141.2M），FOSTER L B CO净利率更高（1.5% vs 0.1%，领先1.4%），FOSTER L B CO同比增速更快（25.1% vs 14.3%），过去两年FOSTER L B CO的营收复合增速更高（13.6% vs 10.2%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Foster L B Co.是一家总部位于美国的专业工业制造企业，主要生产销售工程通道产品、建筑组件及铁路基础设施用品，服务覆盖北美及部分全球地区的商业建筑、交通和工业领域客户。
ATRC vs FSTR — 直观对比
营收规模更大
FSTR
是对方的1.1倍
$141.2M
营收增速更快
FSTR
高出10.9%
14.3%
净利率更高
FSTR
高出1.4%
0.1%
两年增速更快
FSTR
近两年复合增速
10.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $160.4M |
| 净利润 | $108.0K | $2.4M |
| 毛利率 | 77.4% | 19.7% |
| 营业利润率 | 23.0% | 4.9% |
| 净利率 | 0.1% | 1.5% |
| 营收同比 | 14.3% | 25.1% |
| 净利润同比 | — | 1098.3% |
| 每股收益（稀释后） | $0.00 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCFSTR
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $160.4M | ||
| Q3 25 | $134.3M | $138.3M | ||
| Q2 25 | $136.1M | $143.6M | ||
| Q1 25 | $123.6M | $97.8M | ||
| Q4 24 | $124.3M | $128.2M | ||
| Q3 24 | $115.9M | $137.5M | ||
| Q2 24 | $116.3M | $140.8M |
净利润ATRCFSTR
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $2.4M | ||
| Q3 25 | $-267.0K | $4.4M | ||
| Q2 25 | $-6.2M | $2.9M | ||
| Q1 25 | $-6.7M | $-2.1M | ||
| Q4 24 | — | $-242.0K | ||
| Q3 24 | $-7.9M | $35.9M | ||
| Q2 24 | $-8.0M | $2.8M |
毛利率ATRCFSTR
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | 19.7% | ||
| Q3 25 | 75.5% | 22.5% | ||
| Q2 25 | 74.5% | 21.5% | ||
| Q1 25 | 74.9% | 20.6% | ||
| Q4 24 | 74.5% | 22.3% | ||
| Q3 24 | 74.9% | 23.8% | ||
| Q2 24 | 74.7% | 21.7% |
营业利润率ATRCFSTR
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 4.9% | ||
| Q3 25 | 0.2% | 6.0% | ||
| Q2 25 | -4.5% | 5.3% | ||
| Q1 25 | -4.8% | -2.0% | ||
| Q4 24 | -11.7% | 2.4% | ||
| Q3 24 | -6.4% | 5.3% | ||
| Q2 24 | -6.2% | 3.2% |
净利率ATRCFSTR
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | 1.5% | ||
| Q3 25 | -0.2% | 3.1% | ||
| Q2 25 | -4.5% | 2.0% | ||
| Q1 25 | -5.5% | -2.2% | ||
| Q4 24 | — | -0.2% | ||
| Q3 24 | -6.8% | 26.1% | ||
| Q2 24 | -6.9% | 2.0% |
每股收益（稀释后）ATRCFSTR
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $0.22 | ||
| Q3 25 | $-0.01 | $0.40 | ||
| Q2 25 | $-0.13 | $0.27 | ||
| Q1 25 | $-0.14 | $-0.20 | ||
| Q4 24 | $-0.33 | $-0.04 | ||
| Q3 24 | $-0.17 | $3.27 | ||
| Q2 24 | $-0.17 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $4.3M |
| 总债务越低越好 | $61.0M | $42.6M |
| 股东权益账面价值 | $491.7M | $175.3M |
| 总资产 | $644.0M | $330.4M |
| 负债/权益比越低杠杆越低 | 0.12× | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资ATRCFSTR
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $4.3M | ||
| Q3 25 | $147.9M | $3.4M | ||
| Q2 25 | $117.8M | $4.2M | ||
| Q1 25 | $99.9M | $2.6M | ||
| Q4 24 | $122.7M | $2.5M | ||
| Q3 24 | $130.3M | $3.1M | ||
| Q2 24 | $114.0M | $4.0M |
总债务ATRCFSTR
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | $42.6M | ||
| Q3 25 | $61.9M | $58.6M | ||
| Q2 25 | $61.9M | $81.4M | ||
| Q1 25 | $61.9M | $82.3M | ||
| Q4 24 | — | $46.8M | ||
| Q3 24 | $61.9M | $68.4M | ||
| Q2 24 | $61.9M | $87.0M |
股东权益ATRCFSTR
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $175.3M | ||
| Q3 25 | $476.5M | $174.8M | ||
| Q2 25 | $464.5M | $174.4M | ||
| Q1 25 | $454.6M | $170.8M | ||
| Q4 24 | $461.0M | $178.3M | ||
| Q3 24 | $465.0M | $181.9M | ||
| Q2 24 | $462.1M | $147.1M |
总资产ATRCFSTR
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $330.4M | ||
| Q3 25 | $635.4M | $333.9M | ||
| Q2 25 | $608.8M | $349.9M | ||
| Q1 25 | $591.6M | $342.8M | ||
| Q4 24 | $609.3M | $334.6M | ||
| Q3 24 | $615.1M | $344.5M | ||
| Q2 24 | $597.3M | $333.3M |
负债/权益比ATRCFSTR
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | 0.24× | ||
| Q3 25 | 0.13× | 0.33× | ||
| Q2 25 | 0.13× | 0.47× | ||
| Q1 25 | 0.14× | 0.48× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | 0.13× | 0.38× | ||
| Q2 24 | 0.13× | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $19.8M |
| 自由现金流率自由现金流/营收 | — | 12.3% |
| 资本支出强度资本支出/营收 | — | 1.5% |
| 现金转化率经营现金流/净利润 | — | 9.18× |
| 过去12个月自由现金流最近4个季度 | — | $25.2M |
8季度趋势，按日历期对齐
经营现金流ATRCFSTR
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $22.2M | ||
| Q3 25 | $26.7M | $29.2M | ||
| Q2 25 | $21.6M | $10.4M | ||
| Q1 25 | $-11.0M | $-26.1M | ||
| Q4 24 | $5.8M | $24.3M | ||
| Q3 24 | $20.0M | $24.7M | ||
| Q2 24 | $7.4M | $-5.0M |
自由现金流ATRCFSTR
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $19.8M | ||
| Q3 25 | $24.1M | $26.4M | ||
| Q2 25 | $19.0M | $7.7M | ||
| Q1 25 | $-13.2M | $-28.7M | ||
| Q4 24 | $3.1M | $22.3M | ||
| Q3 24 | $16.4M | $21.7M | ||
| Q2 24 | $5.0M | $-7.0M |
自由现金流率ATRCFSTR
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 12.3% | ||
| Q3 25 | 18.0% | 19.1% | ||
| Q2 25 | 13.9% | 5.4% | ||
| Q1 25 | -10.7% | -29.4% | ||
| Q4 24 | 2.5% | 17.4% | ||
| Q3 24 | 14.1% | 15.8% | ||
| Q2 24 | 4.3% | -5.0% |
资本支出强度ATRCFSTR
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 1.5% | ||
| Q3 25 | 1.9% | 2.0% | ||
| Q2 25 | 2.0% | 1.9% | ||
| Q1 25 | 1.8% | 2.6% | ||
| Q4 24 | 2.2% | 1.5% | ||
| Q3 24 | 3.1% | 2.2% | ||
| Q2 24 | 2.1% | 1.5% |
现金转化率ATRCFSTR
| Q1 26 | — | — | ||
| Q4 25 | — | 9.18× | ||
| Q3 25 | — | 6.70× | ||
| Q2 25 | — | 3.61× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | -1.74× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
FSTR
| Rail Technologies And Services Segment | $98.0M | 61% |
| Over Time Output Method | $26.3M | 16% |
| Services | $19.4M | 12% |
| Rail Technologies Products | $10.0M | 6% |
| Over Time Input Method | $8.3M | 5% |
